Review
Peroxisome proliferator activated receptor 
: a potential
therapeutic target in the management of ischaemic heart
disease
J S Sidhu, J C Kaski
Coronary Artery
Disease Unit, Department of Cardiological Sciences, St George's
Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
Correspondence to: Professor Kaski jkaski@sghms.ac.uk
Accepted 22 May 2001
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
In
recent years it has been established that inflammation has a pathogenic
role in atherosclerosis. Experimental studies have suggested that
altering transcription of proinflammatory genes can result in the
inhibition of atherosclerotic disease progression. Peroxisome
proliferator activated receptor 
(PPAR), a member of the nuclear
receptor superfamily of ligand activated transcription factors, is
highly expressed in several organs as well as in atherosclerotic plaques. Agonists of this receptor, such as rosiglitazone,
pioglitazone, and troglitazone, have insulin sensitising actions and
the former two agents are used clinically to treat type II diabetes.
PPAR agonists can also inhibit the transcription of proinflammatory genes within plaques and have antithrombotic effects. Furthermore, PPAR agonists have been shown to inhibit vascular smooth muscle cell
(VSMC) proliferation, which underlies restenosis after percutaneous coronary intervention. This article summarises our current
understanding of the role of PPAR agonists in atherogenesis and
discusses their potential role in the treatment
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Mikaelian, I., Coluccio, D., Morgan, K. T., Johnson, T., Ryan, A. L., Rasmussen, E., Nicklaus, R., Kanwal, C., Hilton, H., Frank, K., Fritzky, L., Wheeldon, E. B.
(2008). Temporal Gene Expression Profiling Indicates Early Up-regulation of Interleukin-6 in Isoproterenol-induced Myocardial Necrosis in Rat. Toxicol Pathol
36: 256-264
[Abstract] [Full Text] -
Marfella, R., D'Amico, M., Esposito, K., Baldi, A., Di Filippo, C., Siniscalchi, M., Sasso, F. C., Portoghese, M., Cirillo, F., Cacciapuoti, F., Carbonara, O., Crescenzi, B., Baldi, F., Ceriello, A., Nicoletti, G. F., D'Andrea, F., Verza, M., Coppola, L., Rossi, F., Giugliano, D.
(2006). The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Rosiglitazone Treatment. Diabetes
55: 622-632
[Abstract] [Full Text] -
Yuan, Z, Liu, Y, Liu, Y, Zhang, J, Kishimoto, C, Wang, Y, Ma, A, Liu, Z
(2005). Cardioprotective effects of peroxisome proliferator activated receptor {gamma} activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor {kappa}B blockade. Heart
91: 1203-1208
[Abstract] [Full Text] -
Sidhu, J. S., Kaposzta, Z., Markus, H. S., Kaski, J. C.
(2004). Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus. Arterioscler. Thromb. Vasc. Bio.
24: 930-934
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
